Access & Legality
    Retatrutide

    Retatrutide Waitlist: How to Be First

    Everyone wants retatrutide. Supply will be limited at launch. Here is how to position yourself for the earliest possible access -- and what to do productively while you wait.

    Published: April 3, 2026•12 min read

    After retatrutide's Phase 2 results (Jastreboff et al., NEJM 2023) showed 24% weight loss, patient interest exploded. The question shifted from "does this work?" to "how do I get it?" But retatrutide is not yet FDA-approved, supply through any channel is limited, and demand far exceeds availability. Smart positioning now can mean earlier access later.

    Access Reality

    No official waitlist exists for retatrutide. Beware of scams charging for "waitlist" access or "guaranteed early supply." Retatrutide is investigational and not FDA-approved.

    Step 1: Start Treatment Now

    The most productive thing you can do while waiting for retatrutide is start losing weight with currently available medications. Compounded semaglutide ($99/mo) offers 15-17% weight loss. Compounded tirzepatide ($125/mo) offers 20-22% weight loss. Both are effective, well-characterized treatments that work. Starting now means you build a relationship with a prescribing provider, establish baseline health data, begin your weight loss journey immediately, and position yourself for an easy transition to retatrutide when available.

    Step 2: Establish a Provider Relationship

    Telehealth providers that specialize in weight loss medications will be among the first to offer retatrutide access when it becomes available -- whether through compounding pharmacies or FDA-approved channels. Having an existing patient relationship means faster access compared to starting from scratch.

    Step 3: Consider Clinical Trial Enrollment

    Phase 3 trials (TRIUMPH program) provide the most assured access to pharmaceutical-grade retatrutide with comprehensive medical monitoring. Search ClinicalTrials.gov for active enrollment opportunities. Discuss eligibility with your physician.

    Step 4: Stay Informed

    Follow reputable medical sources for retatrutide news. FDA decisions, trial results, and availability updates will come through medical journals, FDA announcements, and legitimate medical news sources -- not social media speculation.

    What Not to Do

    • Do not pay for "waitlist" access -- legitimate waitlists are free
    • Do not buy research peptides labeled as retatrutide
    • Do not postpone weight loss waiting for a "better" medication
    • Do not believe guaranteed availability dates from unofficial sources

    To start your weight loss journey today, visit our treatments page.

    Medical Disclaimer

    This article is for educational purposes only. Retatrutide is not FDA-approved. No official waitlist exists. Consult a healthcare provider for treatment decisions.

    Do Not Wait -- Start Today

    Effective weight loss treatments available now. Semaglutide from $99/mo.

    Get Started Today

    More on Retatrutide

    How to Get Retatrutide in 2026

    All current access pathways

    Retatrutide and the FDA: Regulatory Pathway

    When approval might come

    Retatrutide Telehealth Prescriptions

    Getting connected with a provider

    Retatrutide Insurance Coverage

    Costs and coverage outlook

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. — Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. — Rosenstock et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: May 19, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    — u/CSWB101Reddit (r/TirzepatideRX)
    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    — Amy KeithFacebook
    See all community reviews →

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1) — NCT05929066. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    GLP-1 Guide

    First Week GLP-1 Timeline

    Clinician-reviewed Trimi guide to GLP-1: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded GLP-1 option compares to brand alternatives.

    8 minRead More
    GLP-1 Guide

    Retatrutide Weight By BMI

    Clinician-reviewed Trimi guide to retatrutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded retatrutide option compares to brand alternatives.

    8 minRead More
    GLP-1 Guide

    Retatrutide Weight By Week

    Clinician-reviewed Trimi guide to retatrutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded retatrutide option compares to brand alternatives.

    8 minRead More
    GLP-1 Guide

    GLP-1 Erectile Dysfunction Weight

    Clinician-reviewed Trimi guide to GLP-1: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded GLP-1 option compares to brand alternatives.

    8 minRead More

    Start your GLP-1 journey — from $99/mo

    Get Started